PDGFRA and gastrointestinal stromal tumor: Nonetheless, approximately 10–15% of GIST cases lack mutations in these genes and are classified as “wild-type GISTs.” These tumors typically do not respond to imatinib, the standard treatment for GISTs with KIT or PDGFRα mutations (Nishida et al., 2024).